Marco Merlano
Research Subjects
Research Interests
Marco Merlano has a total of 473 co-authors. Here are the top co-authors by number of shared publications:
C. Lo Nigro
11 shared publicationsD. Vivenza
11 shared publicationsL. Lattanzio
11 shared publicationsO. Garrone
11 shared publicationsM Benasso
10 shared publications- Gianmauro Numico
Medical Oncology, AO S.Croce e Carle, Cuneo, Italy
9 shared publications
Latest Publications
- Open Access
- 23 November 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (11) , 414
VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study
The prospective multicenter COMET trial followed a cohort of 306 consecutive metastatic breast cancer patients receiving bevacizumab and paclitaxel as first-line chemotherapy. This study was intended to identify and validate reliable biomarkers to better predict bevacizumab treatment outcomes and allow for a more personalized use of this antiangiogenic agent. To that end, we aimed to establish risk scores for survival prognosis dichotomization based on classic clinico-pathological criteria combined or not with single nucleotide polymorphisms (SNPs). The genomic DNA of 306 patients was extracted and a panel of 13 SNPs, covering seven genes previously documented to be potentially involved in drug response, were analyzed by means of high-throughput genotyping. In receiver operating characteristic (ROC) analyses, the hazard model based on a triple-negative cancer phenotype variable, combined with specific SNPs in VEGFA (rs833061), VEGFR1 (rs9582036) and VEGFR2 (rs1870377), had the highest predictive value. The overall survival hazard ratio of patients assigned to the poor prognosis group based on this model was 3.21 (95% CI (2.33–4.42); p < 0.001). We propose that combining this pharmacogenetic approach with classical clinico-pathological characteristics could markedly improve clinical decision-making for breast cancer patients receiving bevacizumab-based therapy.
- 23 November 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (11) , 414
Open AccessVEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study
The prospective multicenter COMET trial followed a cohort of 306 consecutive metastatic breast cancer patients receiving bevacizumab and paclitaxel as first-line chemotherapy. This study was intended to identify and validate reliable biomarkers to better predict bevacizumab treatment outcomes and allow for a more personalized use of this antiangiogenic agent. To that end, we aimed to establish risk scores for survival prognosis dichotomization based on classic clinico-pathological criteria combined or not with single nucleotide polymorphisms (SNPs). The genomic DNA of 306 patients was extracted and a panel of 13 SNPs, covering seven genes previously documented to be potentially involved in drug response, were analyzed by means of high-throughput genotyping. In receiver operating characteristic (ROC) analyses, the hazard model based on a triple-negative cancer phenotype variable, combined with specific SNPs in VEGFA (rs833061), VEGFR1 (rs9582036) and VEGFR2 (rs1870377), had the highest predictive value. The overall survival hazard ratio of patients assigned to the poor prognosis group based on this model was 3.21 (95% CI (2.33–4.42); p < 0.001). We propose that combining this pharmacogenetic approach with classical clinico-pathological characteristics could markedly improve clinical decision-making for breast cancer patients receiving bevacizumab-based therapy.
- 1 March 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 122, 12-13
OC-019: The phase III study INTERCEPTOR: preliminary results
- 1 March 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 122, 12-13
OC-019: The phase III study INTERCEPTOR: preliminary results
- 1 March 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 122, 19-20
PD-033: Cetuximab + RT shows an excellent long term OS in patients with both high ADCC and high EGFR
- 1 March 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 122, 19-20
PD-033: Cetuximab + RT shows an excellent long term OS in patients with both high ADCC and high EGFR
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi336
Individual ADCC capability predict treatment outcome under cetuximab-based therapy in head and neck cancer?
Background: Cetuximab is a IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) used for the treatment of local advanced-head and neck squamous cell carcinoma (LA-HNSCC). A working mechanism of cetuximab include the ability to develop antibody-dependent cell-mediated cytotoxicity (ADCC), triggered by the interaction of the Fc portion of the antibody with the Fc receptor on the immune cell, mainly on Natural Killer (NK) cells. Invariant NKT (iNKT) cells play an important role in the activation of immune cell subset, including NK cells, and their deficiency is related to poor clinical outcome in LA-HNSCC. The aim of this work was to investigate the predictive role of ADCC and iNKT in LA-HNSCC patients treated with cetuximab-based therapy.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi336
Individual ADCC capability predict treatment outcome under cetuximab-based therapy in head and neck cancer?
Background: Cetuximab is a IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) used for the treatment of local advanced-head and neck squamous cell carcinoma (LA-HNSCC). A working mechanism of cetuximab include the ability to develop antibody-dependent cell-mediated cytotoxicity (ADCC), triggered by the interaction of the Fc portion of the antibody with the Fc receptor on the immune cell, mainly on Natural Killer (NK) cells. Invariant NKT (iNKT) cells play an important role in the activation of immune cell subset, including NK cells, and their deficiency is related to poor clinical outcome in LA-HNSCC. The aim of this work was to investigate the predictive role of ADCC and iNKT in LA-HNSCC patients treated with cetuximab-based therapy.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi337
Prognostic value of HPV infection by E1 detection and p16 expression in 78 oropharyngeal squamous cell carcinomas
Background: HPV infection is a strong prognostic marker in oropharyngeal squamous cell carcinomas (OSCCs). HPV-positive pts are associated with better survival than HPV-negative ones. Currently, the expression of p16 is the standard test to identify HPV positive OSCCs in clinical practice. The combined use of p16 and HPV DNA detection is the recommended standard for clinical research, at least in USA. In the present study we compare the prognostic value of a genomic viral fragment, E1, with p16 expression in a series of OSCC pts in terms of overall survival (OS) and progression free survival (PFS).
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi337
Prognostic value of HPV infection by E1 detection and p16 expression in 78 oropharyngeal squamous cell carcinomas
Background: HPV infection is a strong prognostic marker in oropharyngeal squamous cell carcinomas (OSCCs). HPV-positive pts are associated with better survival than HPV-negative ones. Currently, the expression of p16 is the standard test to identify HPV positive OSCCs in clinical practice. The combined use of p16 and HPV DNA detection is the recommended standard for clinical research, at least in USA. In the present study we compare the prognostic value of a genomic viral fragment, E1, with p16 expression in a series of OSCC pts in terms of overall survival (OS) and progression free survival (PFS).
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi189
Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer
Background: TNM, stage and key biological markers direct the choice of adjuvant chemotherapy. Stage II colon cancer (CC) is a heterogeneous disease with different clinical behavior. For this reason there is a high degree of uncertainty in recommending adjuvant chemotherapy. Pathological features are routinely employed to distinguish high and low risk stage II disease. Adjuvant chemotherapy is usually suggested in the high-risk population. Published data suggest that specific tumor-infiltrating lymphocytes (S-TILs) (CD3 + , CD8 + , CD45RO+) may represent a valuable prognostic tool to drive the decision-making process.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi189
Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer
Background: TNM, stage and key biological markers direct the choice of adjuvant chemotherapy. Stage II colon cancer (CC) is a heterogeneous disease with different clinical behavior. For this reason there is a high degree of uncertainty in recommending adjuvant chemotherapy. Pathological features are routinely employed to distinguish high and low risk stage II disease. Adjuvant chemotherapy is usually suggested in the high-risk population. Published data suggest that specific tumor-infiltrating lymphocytes (S-TILs) (CD3 + , CD8 + , CD45RO+) may represent a valuable prognostic tool to drive the decision-making process.
- 21 September 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, iv86
Prognostic value of hpv infection by e1 detection and p16 expression in 78 oropharyngeal squamous cell carcinomas
Background: Human papillomavirus (HPV) infection is a strong prognostic marker in oropharyngeal squamous cell carcinomas (OSCCs). HPV-positive pts are associated with better survival than HPV-negative ones. The better outcome of HPV-positive pts needs methods to distinguish between HPV and non-HPV associated OSCCs. Currently, the expression of p16 is the standard test to identify HPV positive OSCCs in clinical practice. The combined use of p16 and HPV DNA detection is the recommended standard for clinical research, at least in USA. In the present study we compare the prognostic value of a genomic viral fragment, E1, with p16 expression in a series of OSCC pts in terms of overall survival (OS) and progression free survival (PFS).
- 21 September 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, iv86
Prognostic value of hpv infection by e1 detection and p16 expression in 78 oropharyngeal squamous cell carcinomas
Background: Human papillomavirus (HPV) infection is a strong prognostic marker in oropharyngeal squamous cell carcinomas (OSCCs). HPV-positive pts are associated with better survival than HPV-negative ones. The better outcome of HPV-positive pts needs methods to distinguish between HPV and non-HPV associated OSCCs. Currently, the expression of p16 is the standard test to identify HPV positive OSCCs in clinical practice. The combined use of p16 and HPV DNA detection is the recommended standard for clinical research, at least in USA. In the present study we compare the prognostic value of a genomic viral fragment, E1, with p16 expression in a series of OSCC pts in terms of overall survival (OS) and progression free survival (PFS).
- 21 September 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, iv73
Nab-paclitaxel in clinical practice: preliminary results from MANTEL Study
Background: Metastatic breast cancer (MBC) is an incurable disease. The main goals of treatment are palliation, symptoms control, preserving QoL and prolonging survival. New drugs have contributed to ameliorate the outcome of MBC patients (pts) by increasing response rates (RR) progression free survival (PFS) and, in some setting, overall survival (OS). Taxanes are the most effective drugs in the management of MBC. Nab-Paclitaxel (Nab-P) is a solvent-free albumin-bound taxane showing linear pharmacokinetics, high tumor retention, improved antitumor efficacy, and reduced toxicity.
- 21 September 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, iv73
Nab-paclitaxel in clinical practice: preliminary results from MANTEL Study
Background: Metastatic breast cancer (MBC) is an incurable disease. The main goals of treatment are palliation, symptoms control, preserving QoL and prolonging survival. New drugs have contributed to ameliorate the outcome of MBC patients (pts) by increasing response rates (RR) progression free survival (PFS) and, in some setting, overall survival (OS). Taxanes are the most effective drugs in the management of MBC. Nab-Paclitaxel (Nab-P) is a solvent-free albumin-bound taxane showing linear pharmacokinetics, high tumor retention, improved antitumor efficacy, and reduced toxicity.
- 21 September 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, iv85
Individual ADCC capability predict treatment outcome under cetuximab-based therapy in head and neck cancer?
Introduction: Cetuximab is a IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) used for the treatment of local advanced-head and neck squamous cell carcinoma (LA-HNSCC). The working mechanism of cetuximab include the ability to develop antibody-dependent cell-mediated cytotoxicity (ADCC), triggered by the interaction of the Fc portion of the antibody with the Fc receptor on the immune cell, mainly on Natural Killer (NK) cells. Invariant NKT (iNKT) cells play an important role in the activation of immune cell subset, including NK cells, and their deficiency is related to poor clinical outcome in LA-HNSCC. The aim of this work was to investigate the predictive role of ADCC and iNKT in LA-HNSCC patients treated with cetuximab-based therapy.
- 21 September 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, iv85
Individual ADCC capability predict treatment outcome under cetuximab-based therapy in head and neck cancer?
Introduction: Cetuximab is a IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) used for the treatment of local advanced-head and neck squamous cell carcinoma (LA-HNSCC). The working mechanism of cetuximab include the ability to develop antibody-dependent cell-mediated cytotoxicity (ADCC), triggered by the interaction of the Fc portion of the antibody with the Fc receptor on the immune cell, mainly on Natural Killer (NK) cells. Invariant NKT (iNKT) cells play an important role in the activation of immune cell subset, including NK cells, and their deficiency is related to poor clinical outcome in LA-HNSCC. The aim of this work was to investigate the predictive role of ADCC and iNKT in LA-HNSCC patients treated with cetuximab-based therapy.
- 26 September 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vi12-vi30
Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients
- 26 September 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vi12-vi30
Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients